Employers advocate reform of the 340B Drug Pricing Program, criticizing the mechanism that allows hospitals to acquire medications at steep discounts and bill insured patients at full prices. Industry commentary highlights concerns over pricing transparency and the potential financial strain on employers providing health benefits. This growing scrutiny could shape future policy discussions impacting drug pricing structures and hospital revenue models within the pharmaceutical and insurance sectors.